News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/lucijanic-marko-leuklymph2018-240.jpg)
GPS appears to predict survival in myelofibrosis
- Author:
- Jen Smith
DUBROVNIK, CROATIA—The Glasgow Prognostic Score (GPS) may predict survival in patients with myelofibrosis (MF), according to research presented at...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/DNA-helix-Spencer-Phillips_230.jpg)
Variant not associated with CLL, AIHA, or ITP in certain patients
- Author:
- Jen Smith
DUBROVNIK, CROATIA—New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/leuk-lymph-2018-crowd-dcruz-200.jpg)
System may better predict thrombosis in lymphoma
- Author:
- Jen Smith
DUBROVNIK, CROATIA—An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/eha23-attendees-crediteha-220.jpg)
‘Very encouraging’ results in BPDCN
- Author:
- Jen Smith
STOCKHOLM—Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/EHA2018-230-js.jpg)
Ropeg outperforms HU in PV patients of all ages
- Author:
- Jen Smith
STOCKHOLM—Follow-up data suggest that ropeginterferon alfa-2b (ropeg) provides an advantage over hydroxyurea (HU) for patients with polycythemia...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/pagliara-daria-eha23-240-js-1.jpg)
A ‘highly effective’ strategy for haplo-HSCT
- Author:
- Jen Smith
STOCKHOLM—Researchers have identified a “highly effective” transplant strategy for pediatric patients with primary immunodeficiencies who lack a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/eha23-session-credit-eha-210.jpg)
Drug is convenient alternative for PNH, doc says
- Author:
- Jen Smith
STOCKHOLM—Results of a phase 3 study suggest the long-acting C5 complement inhibitor ravulizumab produces similar results as eculizumab in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/salhotra-eha23-js-240.jpg)
Inhibitor elicits responses in cGVHD
- Author:
- Jen Smith
STOCKHOLM—The ROCK2 inhibitor KD025 produced responses in about two-thirds of patients with steroid-dependent or refractory chronic graft-versus-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/elotuzumab-bms-220.jpg)
MAb doubles ORR, PFS in rel/ref MM
- Author:
- Jen Smith
STOCKHOLM—Adding elotuzumab (E) to treatment with pomalidomide (P) and low-dose dexamethasone (d) can produce “clinically meaningful” results in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/poster-session-EHA-220.jpg)
Inhibitor exhibits activity in B- and T-cell NHLs
- Author:
- Jen Smith
STOCKHOLM—The dual SYK/JAK inhibitor cerdulatinib has demonstrated efficacy in a phase 2 trial of patients with heavily pretreated B- and T-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/goede-eha23-240.jpg)
Combo proves ‘beneficial’ for ‘unfit’ CLL patients
- Author:
- Jen Smith
STOCKHOLM—Obinutuzumab plus chlorambucil (G-Clb) is a “valid and beneficial” frontline treatment option for “unfit” patients with chronic...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/poster-session-EHA-220.jpg)
Umbralisib can revitalize ruxolitinib in MF
- Author:
- Jen Smith
STOCKHOLM—The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/EHA2018-230-js.jpg)
Quizartinib can prolong OS in rel/ref, FLT3-ITD AML
- Author:
- Jen Smith
STOCKHOLM—Phase 3 results suggest the FLT3 inhibitor quizartinib can prolong overall survival (OS) in patients with relapsed/refractory, FLT3-ITD...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/bmt-tandem-crowd-240.jpg)
Promising results with expanded UCB product
- Author:
- Jen Smith
SALT LAKE CITY—An expanded umbilical cord blood (UCB) product can produce favorable outcomes as a stand-alone graft, according to a presentation...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Sugita_Junichi-235.jpg)
Outcomes appear similar with MAC and RIC
- Author:
- Jen Smith
SALT LAKE CITY—New research suggests outcomes may be similar whether patients receive myeloablative conditioning (MAC) or reduced-intensity...